KRAS and non-small cell lung carcinoma: Considering that SHP2 is associated with most RTKs [105], combination therapy with SHP2 inhibitors plus KRAS G12C inhibitors could be an attractive therapeutic strategy for refractory or resistant NSCLC harboring KRAS mutations.